NCOA3 and cancer: Finally, SRC-3KO Tregs appear to confer extremely long-lasting protection against cancer recurrence in mice, suggesting that further work to develop genetically altered SRC-3 KO Tregs is warranted as a cell-based therapeutic agent to treat cancer.